

REMARKS

Claims 1-61 were pending in the application. Claims 1, 18, 37 and 58-61 have been amended to clarify the invention. Claim 11 has been cancelled without prejudice. Therefore claims 1-10 and 12-61 will be pending upon entry of the instant amendment.

Restriction Requirement

In the Office Action, the Examiner has required Applicants to elect a single invention among Groups I – VIII.

Applicants hereby elect, without traverse, Group II, claims 1-37 and 54-57 drawn to compounds and pharmaceutical compositions of formula (I), possessing a benzenecarboxamide core where $Y = -L-R^3$ and $L = -C(=O)NH$ or $-NH(C=O)$ and $X = -phenyl, -pyridinyl$ or $-pyrimidinyl$ and an article of manufacture, comprising packaging material, a compound of claim 1...and a label.

The Examiner further required an election of species if Group II is elected. Applicants hereby elect the compound of example 1, where Y is $L-R^3$, L is $-C(=O)NH-$, R^3 is cyclopropyl, R^1 is methyl, $n=0$ (R^2 is not present), and X phenyl.


It is understood that upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim.

Applicants request rejoinder of the method claims of commensurate scope to the composition of matter claims upon allowance of claims directed to the elected invention, e.g., Applicants respectfully request rejoinder of the subject matter corresponding to Groups IV-VIII upon allowance of the claims embodying the elected invention

Applicants respectfully request that the remarks made herein be entered and made of record in the file history of the present application. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
400 Technology Square
Cambridge, MA 02139
(617) 871-3027



Mei L. Benni
Attorney for Applicants
Reg. No. 45,470

Date: November 17, 2008